• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

ADHD Medication During Pregnancy and Breastfeeding

Women with ADHD have to make a difficult choice regarding whether or not to stop taking ADHD medication during pregnancy and breast-feeding. There are few data on how long-term exposure may affect the foetus.

A study recently published in Molecular Psychiatry shows that children exposed to ADHD medication in the uterus do not develop neurological disorders like hearing or vision impairment seizures, febrile seizures, or IQ impairment. The authors acknowledge the need for more high-quality research.

Risk/Benefit Analysis

Pregnant women who use ADHD medications must weigh the advantages of using them against the risks to the fetus. Physicians do not have the necessary data to provide clear recommendations but they can provide information on the risks and benefits to aid pregnant women in making informed decisions.

A study published in Molecular Psychiatry concluded that women who were taking ADHD medication in early pregnancy did not have a greater risk of fetal malformations, or structural birth defects. Researchers used a vast population-based case-control study to assess the risk of major structural birth defects in babies born to mothers who took stimulants during early pregnancy, as well as those who had not. Pediatric cardiologists and clinical geneticists looked over the cases to ensure correct classification of the cases and to reduce the chance of bias.

However, the researchers' study was not without its flaws. Researchers were unable in the beginning to differentiate the effects caused by the medication from the disorder. This makes it difficult to know whether the limited associations observed in the groups that were exposed are due to medication use or confounding by comorbidities. In addition the study did not study the long-term effects of offspring on their parents.

The study revealed that infants whose mother took ADHD medication during pregnancy were at a slightly higher chance of being admitted to the neonatal care unit (NICU) as compared to those whose mothers did not use any medication during pregnancy or had discontinued taking their medication prior to or during pregnancy. The reason for this was central nervous system disorders. The higher risk of admission was not affected by the stimulant medication used during pregnancy.

Women who were taking stimulant ADHD medication during pregnancy were also at an elevated risk of having a caesarean delivery or having a baby born with a low Apgar score (less than 7). These increases appear to be independent of the type of medication taken during pregnancy.

The researchers suggest that the risk of a small amount with the use of ADHD medications during the early stages of pregnancy may be offset by the greater benefits to both mother and [Redirect Only] child from continued treatment for the woman's condition. Physicians should discuss this with their patients and, if possible, assist them in developing strategies to improve their coping abilities that may minimize the effects of her disorder on her daily functioning and relationships.

medication for adhd and depression Interactions

As more women than ever before are being diagnosed with ADHD and being treated with medication, the issue of whether to continue or end treatment during pregnancy is a question that more and more physicians confront. These decisions are usually made without clear and reliable evidence. Instead, physicians must take into account their own experience in conjunction with the experiences of other physicians and the research on the subject.

The issue of potential risks to infants is particularly tricky. Many of the studies on this issue are based on observational data instead of controlled research and their findings are often contradictory. In addition, Most Popular Adhd Medication studies limit their analysis to live births, which can underestimate the severity of teratogenic effects that could cause abortion or termination of the pregnancy. The study that is discussed in this journal club addresses these shortcomings by analyzing data on live and deceased births.

Conclusion A few studies have found a positive correlation between ADHD medications and certain birth defects However, other studies haven't found a correlation. Most studies have shown an unintended, or slight negative impact. Therefore, a careful risk/benefit analysis must be conducted in every instance.

For many women with ADHD, the decision to discontinue medication is difficult if not impossible. In a recent piece published in Archives of Women's Mental Health by psychologist Jennifer Russell, she notes that stopping ADHD medications during pregnancy can increase depression and feelings of isolation. Furthermore, a loss of medication may affect the ability to perform work-related tasks and safely drive, which are important aspects of a normal life for many people suffering from ADHD.

She suggests women who are unsure about whether or not to stop taking medication because of their pregnancy consider the possibility of educating friends, family members and colleagues on the condition, its impact on daily functioning, and on the benefits of keeping the current treatment regimen. It can also help women feel supported in her decision. Some medications can pass through the placenta. If a woman decides not to take her ADHD medication while breastfeeding, it is crucial to be aware that the medication could be passed on to her infant.

Risk of Birth Defects

As the use of ADHD medication to treat the symptoms of attention deficit hyperactivity disorder (ADHD) increases, so do concerns over the impact that these drugs could have on the fetuses. A recent study published in the journal Molecular Psychiatry adds to the body of information on this topic. Researchers used two huge datasets to analyze more than 4.3 million pregnant women and determine if the use of stimulant medications increased birth defects. Researchers discovered that, while the risk overall is low, first-trimester ADHD exposure to medication was associated with slightly higher risk of specific heart defects like ventriculoseptal defect.

The researchers of the study found no connection between early use of medication and congenital abnormalities like facial clefting, or club foot. The results are consistent with previous studies showing a small but significant increase in the risk of cardiac malformations among women who started taking ADHD medications prior to the time of the birth of their child. The risk increased in the latter half of pregnancy, when a lot of women stopped taking their medication.

Women who took ADHD medications during the first trimester of pregnancy were also more likely to have a caesarean section, a low Apgar score after delivery and a baby that required help breathing at birth. However the authors of the study were not able to eliminate selection bias by limiting the study to women who did not have other medical issues that could have contributed to these findings.

Researchers hope that their research will help doctors when they meet pregnant women. The researchers recommend that, while discussing benefits and risks are adhd meds covered by ohip crucial, the decision about whether to continue or stop medication should be based on the severity of each woman's ADHD symptoms and her requirements.

The authors also advise that, while stopping the medication is an option, it is not a recommended practice because of the high incidence of depression and other mental health issues among women who are pregnant or recently postpartum. Further, the research suggests that women who choose to stop their medications are more likely to have difficulties adjusting to life without them following the baby's arrival.

Nursing

The responsibilities that come with being a new mom can be overwhelming. Women with ADHD may face a lot of challenges when they must manage their symptoms, go to doctor appointments and prepare for the birth of a baby and adjust to a new adhd medication routine. As such, many women choose to continue taking their ADHD medications throughout the course of pregnancy.

The majority of stimulant medicines pass through breast milk in small amounts, therefore the risk for infant who is breastfeeding is low. The rate of medication exposure will differ based on dosage and frequency of administration as well as time of day. Additionally, individual medications enter the baby's system differently through the gastrointestinal tract and breast milk, and the effect of this on a newborn infant is not fully known.

Because of the lack of research, some doctors may be inclined to discontinue stimulant drugs during the course of pregnancy. This is a complicated decision for the patient, who must weigh the benefits of continuing her medication against the potential dangers to the foetus. As long as there is no more information, GPs should ask all pregnant patients about their experience with ADHD and if they are planning or taking to take medication during the perinatal period.

Many studies have shown that women can continue to take their ADHD best medication for adhd combined type in a safe manner during pregnancy and breast-feeding. This has led to an increasing number of patients are choosing to do so and, in consultation with their physician, they have found that the benefits of continuing their current medication far outweigh any potential risks.

It is crucial for women suffering from ADHD who are thinking of breastfeeding to seek out a specialist psychiatrist's advice prior becoming pregnant. They should discuss their medication with their doctor and discuss the pros and cons for continuing treatment. This includes non-pharmacological strategies. Psychoeducation is also necessary to help pregnant women with ADHD be aware of the symptoms and the underlying disorder. They should also be informed about treatment options and strengthen strategies for coping with adhd without medication. This should be an approach that is multidisciplinary, including the GP, obstetricians and psychiatry. Pregnancy counseling should include discussion of a treatment plan for the mother and child, and monitoring for indicators of deterioration, and, if necessary adjustments to the medication regime.